Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
T cell receptors (TCRs) allow T cells to interact with other immune cells and identify and target cancer cells. Upon activation, these TCRs can form giant clusters with other proteins in T cells. The effects of this clustering are unknown though, so Dr. Su established a system that models the TCR signaling pathway to investigate them. He’s found that the clusters enhance the activity of certain enzymes, which promote both T cell activation and T cells’ interactions with tumor cells. These insights may lead to the development of therapies that trigger these clusters to improve the anti-tumor ability of T cells.
University of California, San Francisco | All Cancers, Leukemia | 2014 | Ronald D. Vale, Ph.D.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).